Inhaled corticosteroids or long-acting β-agonists alone or in fixed-dose combinations in asthma treatment: A systematic review of fluticasone/budesonide and formoterol/salmeterol

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2779-2803

  Frois, Christian ^a   Wu, Eric Q ^a   Ray, Saurabh ^b   Colice, Gene L ^c  

^a ANALYSIS GROUP   (United States)

^b ABBOTT LABORATORIES   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

asthma; inhaled corticosteroids; inhaled long acting beta2 agonists

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; SALMETEROL XINAFOATE;

ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GROWTH RETARDATION; HUMAN; PEAK EXPIRATORY FLOW; REVIEW; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DRUG COMBINATIONS; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 74749100173     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.021     Document Type: Review

References (101)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. http://www.ginasthma.com/AboutUs.asp?l1=7&l2=0 Accessed December 19, 2009
2. National Heart Lung and Blood Institute (NHBLI). Guidelines for diagnosis and management of Asthma (EPR-3). http://www.nhlbi.nih.gov/guidelines/asthma/ Accessed December 8, 2008
3. Adams N., Lasserson T.J., Cates C.J., and Jones P.W. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. (2007) CD002310
4. Palmqvist M., Persson G., Lazer L., et al. Inhaled drypowder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J. 10 (1997) 2484-2489
5. Greenstone I.R., Ni Chroinin M.N., Masse V., et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. (2005) CD005533
6. National Institute for Health and Clinical Excellence (NHS). Search results for asthma. http://www.nice.org.uk/search/searchresults.jsp?keywords=asthma&sear chType=all Accessed October 20, 2008
7. Lasserson T.J., Cates C.J., Ferrara G., and Casaku K. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. (2008) CD004106
8. Tee A.K., Koh M.S., Gibson P.G., et al. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. (2007) CD001281
9. Ducharme F.M., Lasserson T.J., and Cates C.J. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. (2006) CD003137
10. Shi L. Health Services Research Methods. 2nd ed. (2008), Thomson/Delmar Learning, Clifton Park, NY
11. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Transparent reporting of systematic reviews and meta-analysis. http://www.prismastatement.org/ Accessed September 28, 2009
12. Lee D.K., Jackson C.M., Currie G.P., et al. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol. 56 (2003) 494-500
13. Bisgaard H., Le Roux P., Bjåmer D., et al. Budesonide/ formoterol maintenance plus reliever therapy: A new strategy in pediatric asthma. Chest. 130 (2006) 1733-1743
14. Bateman E.D., Jacques L., Goldfrad C., et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol. 117 (2006) 563-570
15. Bergmann K.-C., Lindemann L., Braun R., and Steinkamp G. Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly. 134 (2004) 50-58
16. Hoekx J.C., Hedlin G., Pedersen W., et al. Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). Eur Respir J. 9 (1996) 2263-2272
17. Ferguson A.C., Spier S., Manjra A., et al. Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide. J Pediatr. 134 (1999) 422-427
18. Agertoft L., and Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone pro-pionate and budesonide: A dose response study. Eur Respir J. 10 (1997) 1507-1512
19. Lipworth B.J., Dempsey O.J., and Aziz I. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Chest. 118 (2000) 321-328
20. Nightingale J.A., Rogers D.F., and Barnes P.J. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest. 121 (2002) 1401-1406
21. Van Veen A., Weller F.R., Wierenga E.A., et al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther. 16 (2003) 153-161
22. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 171 (2005) 129-136
23. Ayres J.G., Bateman E.D., Lundbäck B., Harris T.A., and International Study Group. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J. 8 (1995) 579-586
24. Heinig J.H., Boulet L.P., Croonenborghs L., and Möllers M.J. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respir Med. 93 (1999) 613-620
25. Williams J., Richards K.A., and UK Study Group. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. Br J Clin Pract. 51 (1997) 147-153
26. Steinmetz K.O., Volmer T., Trautmann M., and Kielhorn A. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Investig. 16 (1998) 117-123
27. Kuna P., Joubert J.R., Greefhorst L.A., and Magnussen H. A randomized, doubleblind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone drypowder inhalers in adults with mild to moderate asthma [published correction appears in Clin Ther. 2003; 25:2634]. Clin Ther. 25 (2003) 2182-2197
28. Molimard M., Martinat Y., Rogeaux Y., et al. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med. 99 (2005) 770-778
29. Agertoft L., and Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol. 99 (1997) 773-780
30. Kannisto S., Voutilainen R., Remes K., and Korppi M. Efficacy and safety of inhaled steroid and cromone treatment in school-age children: A randomized pragmatic pilot study. Pediatr Allergy Immunol. 13 (2002) 24-30
31. Phillips K., Oborne J., Lewis S., et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax. 59 (2004) 26-30
32. Nielsen L.P., and Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 162 (2000) 2053-2057
33. Schermer T.R., Hoff W.J., Greefhorst A.P., et al. Profiles of measured and perceived bronchodilation. A placebocontrolled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. Pulm Pharmacol Ther. 17 (2004) 205-212
34. Van Noord J.A., Smeets J.J., Raaijmakers J.A., et al. Salmeterol versus formot- erol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J. 9 (1996) 1684-1688
35. Palmqvist M., Ibsen T., Mellén A., and Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 160 (1999) 244-249
36. Brambilla C., Le Gros V., Bourdeix I., and Efficacy of Foradil in Asthma (ERORA) French Study Group. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: A multicenter, randomized, openlabel, parallel-group study. Clin Ther. 25 (2003) 2022-2036
37. Condemi J.J. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: A multicenter, randomized, open-label trial. Clin Ther. 23 (2001) 1529-1541
38. Grembiale R.D., Pelaia G., Naty S., et al. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther. 15 (2002) 463-466
39. Politiek M.J., Boorsma M., and Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholineinduced severe bronchoconstriction. Eur Respir J. 13 (1999) 988-992
40. Pohunek P., and Tal A. Budesonide and formoterol in a single inhaler controls asthma in adolescents. Int J Adolesc Med Health. 16 (2004) 91-105
41. Richter K., Janicki S., Jörres R.A., and Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J. 19 (2002) 865-871
42. Lemaigre V., Van den Bergh O., Smets A., et al. Effects of longacting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchus obstruction. Respir Med. 100 (2006) 348-353
43. Rabe K.F., Jörres R., Nowak D., et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis. 147 (1993) 1436-1441
44. Rutten-van Mölken M.P., van Doorslaer E.K., and Till M.D. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. PharmacoEconomics. 14 (1998) 671-684
45. Kuna P., Creemers J.P., Vondra V., et al. Once-daily dosing with budesonide/formoterol compared with twicedaily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir Med. 100 (2006) 2151-2159
46. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 164 (2001) 1392-1397
47. Corren J., Korenblat P.E., Miller C.J., et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 29 (2007) 823-843
48. Noonan M., Rosenwasser L.J., Martin P., et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: A randomised clinical trial. Drugs. 66 (2006) 2235-2254
49. Haahtela T., Tamminen K., Malmberg L.P., et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J. 28 (2006) 748-755
50. Jenkins C., Kolarikova R., Kuna P., et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology. 11 (2006) 276-286
51. Lalloo U.G., Malolepszy J., Kozma D., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 123 (2003) 1480-1487
52. Morice A.H., Peterson S., Beckman O., and Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/ formoterol in children with asthma: A superiority and therapeutic equivalence study. Pulm Pharmacol Ther. 21 (2008) 152-159
53. Pohunek P., Kuna P., Jorup C., et al. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [published correction appears in Pediatr Allergy Immunol. 2006; 17:551]. Pediatr Allergy Immunol 17 (2006) 458-465
54. Rabe K.F., Pizzichini E., Ställberg B., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest. 129 (2006) 246-256
55. Scicchitano R., Aalbers R., Ukena D., et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 20 (2004) 1403-1418
56. Tal A., Simon G., Vermeulen J.H., et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 34 (2002) 342-350
57. Zetterström O., Buhl R., Mellem H., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 18 (2001) 262-268
58. Sovani M.P., Whale C.I., Oborne J., et al. Poor adherence with inhaled corticosteroids for asthma: Can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract. 58 (2008) 37-43
59. Dahlén B., Lantz A.-S., Ihre E., et al. Effect of formoterol with or without budesonide in repeated low-dose allergen challenge. Eur Respir J. 33 (2009) 747-753
60. Kavuru M., Melamed J., Gross G., et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, doubleblind, placebo-controlled trial. J Allergy Clin Immunol. 105 (2000) 1108-1116
61. Lundback B., Ronmark E., Lindberg A., et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med. 100 (2006) 2-10
62. Murray J., Rosenthal R., Somerville L., et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 93 (2004) 351-359
63. Nathan R.A., Dorinsky P., Rosenzweig J.R., et al. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. J Asthma. 40 (2003) 815-822
64. Nelson H.S., Wolfe J.D., Gross G., et al. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol. 91 (2003) 263-269
65. Pearlman D.S., Peden D., Condemi J.J., et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-tomoderate persistent asthma. J Asthma. 41 (2004) 797-806
66. Pearlman D.S., Stricker W., Weinstein S., et al. Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 82 (1999) 257-265
67. Shapiro G., Lumry W., Wolfe J., et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med. 161 (2000) 527-534
68. Ind P.W., Dal Negro R., Colman N.C., et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med. 97 (2003) 555-562
69. Aubier M., Pieters W.R., Schlösser N.J., and Steinmetz K.O. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 93 (1999) 876-884
70. Barnes N.C., Jacques L., Goldfrad C., and Bateman E.D. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: Integrated analysis of four randomised trials. Respir Med. 101 (2007) 2358-2365
71. Bateman E.D., Clark T.J., Frith L., et al., Goal Investigators Group. Rate of response of individual asthma control measures varies and may overestimate asthma control: An analysis of the goal study. J Asthma. 44 (2007) 667-673
72. Bateman E.D., Silins V., and Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med. 95 (2001) 136-146
73. Boonsawat W., Goryachkina L., Jacques L., and Frith L. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma: A placebo-controlled comparison. Clin Drug Investig. 28 (2008) 101-111
74. Busse W., Koenig S.M., Oppenheimer J., et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol. 111 (2003) 57-65
75. Condemi J.J., Goldstein S., Kalberg C., et al., Salmeterol Study Group. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol. 82 (1999) 383-389
76. Currie G.P., Stenback S., and Lipworth B.J. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol. 56 (2003) 11-17
77. Houghton C.M., Lawson N., Borrill Z.L., et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir Res. 8 (2007) 52
78. Koopmans J.G., Lutter R., Jansen H.M., et al. Adding salmeterol to an inhaled corticosteroid: Long term effects on bronchial inflammation in asthma. Thorax. 61 (2006) 306-312
79. Rojas R.A., Paluga I., Goldfrad C.H., et al. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: A comparison with fluticasone propionate. J Asthma. 44 (2007) 437-441
80. Strand A.M., Luckow A., and Danish INititative for Asthma treatment. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med. 98 (2004) 1008-1015
81. Peters S.P., Anthonisen N., Castro M., et al., American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma [published correction appears in N Engl J Med. 2007;357:728]. N Engl J Med. 356 (2007) 2027-2039
82. Schermer T.R., Albers J.M., Verblackt H.W., et al. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. Fam Pract. 24 (2007) 181-188
83. Wallin A., Sue-Chu M., Bjermer L., et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 112 (2003) 72-78
84. Weiler J.M., Nathan R.A., Rupp N.T., et al. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol. 94 (2005) 65-72
85. Woodcock A.A., Bagdonas A., Boonsawat W., et al., GOAL Steering Committee & Investigators. Improvement in asthma endpoints when aiming for total control: Salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim Care Respir J. 16 (2007) 155-161
86. Chuchalin A., Jacques L., and Frith L. Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. Clin Drug Investig. 28 (2008) 169-181
87. Jarjour N.N., Wilson S.J., Koenig S.M., et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol. 118 (2006) 44-52
88. Currie G.P., Bates C.E., Lee D.K., et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol. 59 (2003) 11-15
89. Koenig S.M., Ostrom N., Pearlman D., et al. Deterioration in asthma control when subiects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". J Asthma. 45 (2008) 681-687
90. Pearlman D., Qaqundah P., Matz J., et al. Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Pediatr Pulmonol. 44 (2009) 429-435
91. Coutts J.A., Gibson N.A., and Paton J.Y. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 67 (1992) 332-333
92. Rosenhall L., Elvstrand A., Tilling B., et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med. 97 (2003) 702-708
93. Shepherd J., Rogers G., Anderson R., et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 12 (2008) iii-iv
94. Shepherd J., Rogers G., Anderson R., et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 12 (2008) 1-360
95. Barnes N.C., Thwaites R.M., and Price M.J. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med. 93 (1999) 402-407
96. Stempel D.A., Stanford R.H., Thwaites R., and Price M.J. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin Ther. 22 (2000) 1562-1574
97. Derendorf H., and Meltzer E.O. Molecular and clinical pharmacology of intranasal corticosteroids: Clinical and therapeutic implications. Allergy 63 (2008) 1292-1300
98. Price D.B., Williams A.E., and Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adiustable maintenance dosing: Impact on health-related quality of life. Respir Res. 8 (2007) 46
99. Vogelmeier C., D'Urzo A., Pauwels R., et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option [published correction appears in Eur Respir J. 2005;26:1191]?. Eur Respir J. 26 (2005) 819-828
100. FitzGerald J.M., Boulet L.P., and Follows R.M. The CONCEPT trial: A 1-year, multicenter, randomized, doubleblind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adiustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 27 (2005) 393-406
101. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398-b1-01-FDA.pdf Accessed September 28, 2009